Clinical Observation On The Treatment Of Early Rheumatoid Arthritis With Wind,cold And Dampness Resistance Syndrome By Modified Qubi Prescription

Purpose:In order to provide theoretical basis and data support for clinical treatment of early rheumatoid arthritis,the efficacy and safety of the modified Qubi prescription in the treatment of early rheumatoid arthritis(wind-cold dampness obstruction syndrome)were observed.Methods:From January 2019 to January 2020,60 patients with rheumatoid arthritis with early wind,cold and dampness resistance syndrome who met the inclusion criteria were selected and randomly grouped according to the random number table,30 cases in the trial group and 30 cases in the control group.The control group was given methotrexate and folic acid tablets orally;the experimental group was treated with traditional Chinese medicine to improve Qubi prescription.If the patient is suffering from pain and severe sleep effects,take celecoxib capsules orally.both groups were treated continuously for 3 months.Collect the changes of symptoms,signs,laboratory examination indexes,total effective rate of TCM symptoms and curative effect of DAS28 integral before and after treatment in the two groups.Data obtained were statistically analyzed using SPSS22.0 software.Results:1.A total of 60 patients were included in this study,of which 59 patients completed this study,and one case in the test group fell off because of refusing to continue the test after trauma.Because the treatment course of the above patients was not more than half,the total shedding rate was 1.67% according to the invalid case treatment.2.Prior to treatment,there was no significant difference in sex,age,course of disease,number of joint tenderness,number of joint swelling,self-evaluation(VAS)of of the current disease(VAS),morning stiffness time and CRP 、 ESR between the two groups(P>0.05).3.The number of self-articular tenderness,the number of joint swelling,the self-evaluation(VAS),the time of morning stiffness and the CRP 、 ESR of the patients on the overall condition of the current disease in the two groups decreased significantly before treatment(P<0.01).After treatment,the difference between CRP two groups was statistically significant(P<0.05).4.The difference between the two groups was significant compared with the individual symptom score of TCM before and after treatment(P<0.01).After treatment,there were significant differences in joint pain,joint swelling,chills and heavy limbs(P<0.05).After treatment,the difference was statistically significant(P<0.05).5.For the improvement of DAS28 standards,the total effective rate of the test group was93.1%,and the total effective rate of the control group was 73.3%,After statistical treatment,the difference was statistically significant(P<0.05).The total effective rate of TCM syndromes in the experimental group was 93.1%,and that in the control group was 70.00%,the difference was statistically significant after statistical treatment(P<0.05).6.Compared the incidence of adverse reactions after treatment between the two groups,the incidence of adverse reactions in the experimental group was 3.45%,and the incidence of adverse reactions in the control group was 10%.After statistical treatment,the difference was not statistically significant(P>0.05).Conclusion:The overall efficacy of modified qubi decoction combined with methotrexate in the treatment of patients with early rheumatoid arthritis(wind-cold dampness obstruction syndrome)was better than that of the simple use of methotrexate,and the adverse reactions were not increased,and the safety was good,which provided the basis for the further clinical application of this scheme.It is suggested that the modified Qubi decoction has good curative effect and good safety in the treatment of early rheumatoid arthritis.